SCHEMBL6179869

SCHEMBL6179869

Fc1ccc([C@@H]2CCCN2)cc1F

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.53
CHRNB2 P17787 2/20 0.46
CHRNA7 P36544 2/20 0.46
CHRNA4 P43681 2/20 0.46
PARP1 P09874 8/20 0.44
PARP2 Q9UGN5 3/20 0.44
KDM1A O60341 1/20 0.42
MAOB P27338 1/20 0.42
MEN1 O00255 2/20 0.41
CYP2D6 P10635 2/20 0.41
CYP2C19 P33261 2/20 0.41
KMT2A Q03164 2/20 0.41
POLB P06746 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2A6 P11509 1/20 0.41
CYP2C9 P11712 1/20 0.41
MKNK1 Q9BUB5 1/20 0.41
MAP4K4 O95819 1/20 0.40
CSF1R P07333 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30504206 1.00 L3MBTL1 (0.53) L3MBTL1CHRNB2CHRNA7CHRNA4PARP1
SCHEMBL3330878 1.00 L3MBTL1 (0.53) L3MBTL1CHRNB2CHRNA7CHRNA4PARP1
SCHEMBL1765187 0.95 L3MBTL1 (0.47) L3MBTL1CHRNB2CHRNA7CHRNA4PARP1
SCHEMBL172513 0.86 KDM1A (0.45) L3MBTL1CHRNB2CHRNA7CHRNA4KDM1A
SCHEMBL24746228 0.84 L3MBTL1 (0.49) L3MBTL1CHRNB2CHRNA7CHRNA4PARP1
SCHEMBL6177583 0.84 L3MBTL1 (0.49) L3MBTL1CHRNB2CHRNA7CHRNA4PARP1
SCHEMBL206683 0.84 L3MBTL1 (0.49) L3MBTL1CHRNB2CHRNA7CHRNA4PARP1
SCHEMBL17529583 0.84 L3MBTL1 (0.49) L3MBTL1CHRNB2CHRNA7CHRNA4PARP1
SCHEMBL22097299 0.84 L3MBTL1 (0.49) L3MBTL1CHRNB2CHRNA7CHRNA4PARP1
SCHEMBL166889 0.84 L3MBTL1 (0.49) L3MBTL1CHRNB2CHRNA7CHRNA4PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230365546-A1 5-SUBSTITUTED INDOLE 3-AMIDE DERIVATIVES, PREPARATION METHOD AND USE THEREOF ORIGIANT PHARMACEUTICAL CO., LTD (CN) 2023-11-16 US disclosed
EP-1165510-B1 1-ARENESULFONYL-2-ARYL-PYRROLIDINE AND PIPERIDINE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS HOFFMANN LA ROCHE (CH) 2005-09-28 EP disclosed
EP-1165510-A1 1-ARENESULFONYL-2-ARYL-PYRROLIDINE AND PIPERIDINE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2002-01-02 EP disclosed
US-6284785-B1 HAVING ACTIVITY AS LIGANDS OF METABOTROPIC GLUTAMATE RECEPTORS HOFFMANN- LA ROCHE INC. 2001-09-04 US disclosed
WO-2000058285-A1 1-ARENESULFONYL-2-ARYL-PYRROLIDINE AND PIPERIDINE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2000-10-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365546-A1 5-SUBSTITUTED INDOLE 3-AMIDE DERIVATIVES, PREPARATION METHOD AND USE THEREOF RIPK1, RIPK3, RIPK2 L3MBTL1 3099/4885CHRNB2 3758/4885CHRNA7 2486/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.